Literature DB >> 24247259

Viral hepatitis: is it the end of the line for interferon therapy for hepatitis C?

Isobel Leake.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24247259     DOI： 10.1038/nrgastro.2013.224

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  2 in total

1.  Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.

Authors:  Gregory T Everson; Karen D Sims; Maribel Rodriguez-Torres; Christophe Hézode; Eric Lawitz; Marc Bourlière; Veronique Loustaud-Ratti; Vinod Rustgi; Howard Schwartz; Harvey Tatum; Patrick Marcellin; Stanislas Pol; Paul J Thuluvath; Timothy Eley; Xiaodong Wang; Shu-Pang Huang; Fiona McPhee; Megan Wind-Rotolo; Ellen Chung; Claudio Pasquinelli; Dennis M Grasela; David F Gardiner
Journal:  Gastroenterology       Date:  2013-10-30       Impact factor: 22.682

2.  Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Authors:  Eric Lawitz; Fred F Poordad; Phillip S Pang; Robert H Hyland; Xiao Ding; Hongmei Mo; William T Symonds; John G McHutchison; Fernando E Membreno
Journal:  Lancet       Date:  2013-11-05       Impact factor: 79.321
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.